Stocks expected to have increasing option volume: MSTR IOVA CHRS CYTK
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'
December 27, 2023 1:43 PM ESTTruist Securities analyst Srikripa Devarakonda raised the price target on Cytokinetics (NASDAQ: CYTK) to $86.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Following mgmt conference call on Ph3 SEQUOIA-HCM data and speaking with mgmt postconference call, our conviction around best-in-class potential for... More
Cytokinetics (CYTK) PT Raised to $107 at Oppenheimer, 'We Stay Bullish'
December 27, 2023 1:42 PM ESTOppenheimer analyst Justin Kim raised the price target on Cytokinetics (NASDAQ: CYTK) to $107.00 (from $54.00) while maintaining a Outperform rating.
The analyst comments "Aficamten appears on course toward a best-in-class trajectory in the treatment of oHCM following Phase 3 SEQUOIA results. With the call offering... More
